Molecular Pharmaceutics p. 770 - 780 (2017)
Update date:2022-08-11
Topics:
Yang, Dongzhi
Comeau, Anthony
Bowen, Wayne D.
Mach, Robert H.
Ross, Brian D.
Hong, Hao
Van Dort, Marcian E.
High overexpression of sigma (σ) receptors (σ1 and σ2 subtypes) in a variety of human solid tumors has prompted the development of σ receptor-targeting radioligands, as imaging agents for tumor detection. A majority of these radioligands to date target the σ2 receptor, a potential marker of tumor proliferative status. The identification of approximately equal proportions of both σ receptor subtypes in prostate tumors suggests that a high affinity, dual σ receptor-targeting radioligand could potentially provide enhanced tumor targeting efficacy in prostate cancer. To accomplish this goal, we designed a series of ligands which bind to both σ receptor subtypes with high affinity. Ligand 3a in this series, displaying optimal dual σ receptor subtype affinity (σ1, 6.3 nM; σ2, 10.2 nM) was radiolabeled with fluorine-18 (18F) to give [18F]3a and evaluated as a σ receptor-targeting radioligand in the mouse PC-3 prostate tumor model. Cellular assays with PC-3 cells demonstrated that a major proportion of [18F]3a was localized to cell surface σ receptors, while ~10% of [18F]3a was internalized within cells after incubation for 3.5 h. Serial PET imaging in mice bearing PC-3 tumors revealed that uptake of [18F]3a was 1.6 ± 0.8, 4.4 ± 0.3, and 3.6 ± 0.6% ID/g (% injection dose per gram) in σ receptor-positive prostate tumors at 15 min, 1.5 h, and 3.5 h postinjection, respectively (n = 3) resulting in clear tumor visualization. Blocking studies conducted with haloperidol (a nonselective inhibitor for both σ receptor subtypes) confirmed that the uptake of [18F]3a was σ receptor-mediated. Histology analysis confirmed similar expression of σ1 and σ2 in PC-3 tumors which was significantly greater than its expression in normal organs/tissues such as liver, kidney, and muscle. Metabolite studies revealed that >50% of radioactivity in PC-3 tumors at 30 min postinjection represented intact [18F]3a. Prominent σ receptor-specific uptake of [18F]3a in prostate tumors and its subsequent clear visualization with PET imaging indicate potential utility for the diagnosis of prostate carcinoma.
View MoreChengdu Green Young Biopharmaceutical INC
Contact:+86-28-85337952
Address:1-B-26,Tianhe Industry Park, No.1480 of Tianfu Road,Chengdu,P.R.China,610000
SHANDONG CREDAGRI CHEMICAL CO., LTD.
Contact:+86-531-88872050
Address:ROOM 601A, BUILDING 2, SHUNTAI SQUARE, NO. 2000 SHUNHUA ROAD, HI-TECH DEVELOPMENT ZONE, JINAN, CHINA.
Oren Hydrocarbons (Qingdao) Co., Ltd.
Contact:+86-532-68607667-801
Address:Room 3 # 302, No.9 Qingyun Road, Qingdao, China
Suzhou Sibian Chemical Technology Co., Ltd
website:http://www.sibianpharm.com
Contact:+8618169181984,+8618013186906
Address:Room1404,BuildingA,Jiabao Square No.323 Baodai East Road,Wuzhong District,Suzhou Jiangsu China (215128)
Jinan Hongfangde Pharmatech Co.,Ltd
Contact:86-531-88870908
Address:F Bldg. West Unit North Area of Univ. Tech. Garden Xinyu Rd. Jinan New & High Tech Industry Development Zone Shandong, China
Doi:10.1039/c5cc00347d
(2015)Doi:10.3762/bjoc.14.186
(2018)Doi:10.1246/cl.2011.682
(2011)Doi:10.1021/jo01061a054
(1961)Doi:10.1016/j.crci.2011.04.008
(2011)Doi:10.1021/ja01399a024
(1928)